RA Capital Management Announces Close of $1.4 Billion Acquisition of Aliada Therapeutics by AbbVie

Closing marks second significant acquisition from RA Capital's Raven incubator in 2024, and first acquisition of a company built by Raven from a technology platform in-licensed from a large pharmaceutical company

BOSTON, Dec. 11, 2024 /PRNewswire/ -- RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today announced that AbbVie has closed its $1.4 billion acquisition of RA Capital's portfolio company Aliada Therapeutics.

Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier-crossing technology that enhances delivery of targeted drugs into the central nervous system.

Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.), RA Capital, and Raven (RA Capital's healthcare incubator) co-founded Aliada and co-led the series seed financing in 2021 to advance the MODEL™ platform created by Johnson & Johnson scientists that was licensed to Aliada at its inception.

"Congratulations to the Aliada and AbbVie teams and our fellow investors on the close of this transaction," said Joshua Resnick, MD, Senior Managing Director at RA Capital Management and former board director at Aliada. "The acquisition of Aliada is the second significant acquisition of a Raven-grown company this year, joining Novartis' $1 billion upfront acquisition of radiopharmaceutical developer Mariana Oncology in May."

"Delivering therapeutics across the blood-brain barrier with a low-volume, subcutaneous injection would be revolutionary for treating Alzheimer's disease and other neurological disorders, and has long been a dream in the field," said Laura Tadvalkar, PhD, Managing Director at RA Capital Management and former board chair at Aliada. "We look forward to following ALIA-1758's progress through the clinic, as AbbVie advances this important medicine for Alzheimer's disease patients."

About Raven

Raven is RA Capital Management's healthcare incubator. Raven's experienced team of scientists, operators, and innovators bring deep sector expertise, insight and executional capabilities across therapeutics, diagnostics, devices, and services. Raven builds companies: from originating and incubating new ideas to accelerating compelling innovations and rejuvenating promising assets.

About RA Capital

Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by our TechAtlas internal research division, and Raven, RA Capital's company creation team, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 175 employees and over $10 billion in assets under management.

The companies presented herein were selected to demonstrate a potential successful outcome of a company being incubated within our Raven incubator. They are not intended to represent a complete picture of RA Capital's portfolio, its exposures, risks or potential for positive or negative returns. Past performance is not indicative of future results.

SOURCE RA Capital Management, LP